N
|
835
|
370
|
–
|
Age (years), median (IQR)
|
64 (56–75)
|
69 (57–78)
|
0.001
|
Male, n (%)
|
430 (51.5)
|
210 (56.8)
|
0.450
|
BMI (kg/m2), median (IQR)
|
26.8 (24.2–28.7)
|
27.2 (24.3–28.8)
|
0.312
|
Stroke severity, median NIHSS score (IQR)
|
6 (3–9)
|
11 (6–16)
|
0.005
|
Lesion volumes (mL), median (IQR)
|
32 (7–61)
|
48 (14–75)
|
0.009
|
mRS at 3 months, median (IQR)
|
1 (0–2)
|
1 (1–2)
|
0.252
|
Vascular risk factors (%)
|
Hypertension
|
67.1
|
70.2
|
0.683
|
Diabetes mellitus
|
34.1
|
38.3
|
0.597
|
Coronary heart disease
|
31.1
|
34.0
|
0.706
|
Family history for stroke
|
21.0
|
25.5
|
0.503
|
Current smoking
|
22.2
|
23.4
|
0.856
|
Pre-stroke treatment (%)
|
Antiplatelet agents
|
31.7
|
34.0
|
0.765
|
Anticoagulants
|
21.0
|
23.4
|
0.718
|
Endovascular/surgical revascularization (%)
|
Family history of psychiatric disorders (%)
|
10.2
|
27.7
|
0.002
|
Widowhood (%)
|
9.0
|
25.5
|
0.003
|
Living with offspring (%)
|
10.2
|
27.7
|
0.002
|
Stroke etiology (%)
| | |
0.623
|
Atherothrombotic
|
32.9
|
29.8
| |
Cardioembolic
|
28.7
|
25.5
|
Lacunar
|
16.8
|
23.4
|
Unknown
|
21.6
|
21.3
|
Lesion location (%)
| | |
0.371
|
Frontal
|
26.9
|
21.3
| |
Parietal
|
14.4
|
19.1
|
Basal ganglia
|
20.4
|
21.3
|
Posterior fossa
|
17.4
|
21.3
|
Other
|
21.0
|
17.0
|
Laboratory findings, median (IQR)
|
Glucose (mmol L−1)
|
6.18 (5.54–6.75)
|
6.22 (5.58–6.85)
|
0.206
|
Hs-CRP (mg dL−1)
|
0.48 (0.24–0.69)
|
0.75 (0.46–1.23)
|
0.009
|
HCY (mmol L−1)
|
13.8 (9.6–16.5)
|
17.2 (12.1–21.6)
|
0.018
|
TC (mmol L−1)
|
4.86 (4.32–5.36)
|
4.90 (4.32–5.41)
|
0.428
|
TG (mmol L−1)
|
1.89 (1.43–2.21)
|
1.88 (1.40–2.26)
|
0.501
|
HDL-C (mmol L−1)
|
1.16 (1.03–1.24)
|
1.18 (1.05–1.29)
|
0.332
|
LDL-C (mmol L−1)
|
2.48 (2.11–2.76)
|
2.40 (2.04–2.83)
|
0.242
|
IL-6 (pg mL−1)
|
101.2 (76.5–138.6)
|
132.2 (102.3–164.8)
|
0.003
|
HOMA-IR
|
2.13 (1.52–3.04)
|
2.20 (1.62–3.11)
|
0.151
|
Serotonin (ng mL−1)
|
1.65 (0.39–3.83)
|
1.18 (0.35–2.96)
|
< 0.001
|
Irisin (ng mL−1)
|
120.3 (77.6–164.8)
|
74.2 (60.4–108.4)
|
< 0.001
|